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Background: Chemicals of herbal products may cause unexpected toxicity or adverse effect by the potential for
alteration of the activity of CYP450 when co-administered with other drugs. Eleutherococcus senticosus (ES), has been
widely used as a traditional herbal medicine and popular herbal dietary supplements, and often co-administered
with many other drugs. The main bioactive constituents of ES were considered to be eleutherosides including
eleutheroside B (EB) and eleutheroside E (EE). This study was to investigate the effects of EB and EE on CYP2C9,
CYP2D6, CYP2E1 and CYP3A4 in rat liver microsomes in vitro.
Method: Probe drugs of tolbutamide (TB), dextromethorphan (DM), chlorzoxazone (CLZ) and testosterone (TS) as
well as eleutherosides of different concentrations were added to incubation systems of rat liver microsomes in vitro.
After incubation, validated HPLC methods were used to quantify relevant metabolites.
Results: The results suggested that EB and EE exhibited weak inhibition against the activity of CYP2C9 and CYP2E1,
but no effects on CYP2D6 and CYP3A4 activity. The IC50 values for EB and EE were calculated to be 193.20 μM and
188.36 μM for CYP2E1, 595.66 μM and 261.82 μM for CYP2C9, respectively. Kinetic analysis showed that inhibitions
of CYP2E1 by EB and EE were best fit to mixed-type with Ki value of 183.95 μM and 171.63 μM, respectively.
Conclusions: These results indicate that EB and EE may inhibit the metabolism of drugs metabolized via CYP2C9
and CYP2E1, and have the potential to increase the toxicity of the drugs.
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Eleutherococcus senticosus (ES, Acanthopanax sentico-
sus), also called Siberian ginseng in the Siberian Taiga re-
gion and Ciwujia in China, belongs to the family of
Araliaceae, are mainly distributed in the far-eastern re-
gion of Russia, the northeastern of China, Japan and
Korea. It is a medicinal herb that dates back more than
2000 years according to Chinese medicine records and is
also known as a powerful tonic herb with an impressive
range of health benefits. This medicinal plant is not only
popular in China and Russia, but also one of the 10
popular herbal dietary supplements used in the United
States [1]. Recently, ES has drawn increasingly attention* Correspondence: liugaofengwty@126.com
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reproduction in any medium, provided the ordue to its excellent effects on invigorating spleen, beni-
fitting liver and nourishing kidney [2], and lots of chem-
ical, pharmacological and clinical studies on ES have
been carried out all over the world [3,4]. The main bio-
active constituents of ES were considered to be
eleutherosides including eleutheroside B (EB) and
eleutheroside E (EE) (Figure 1). As the quality standard
of ES, the amount of EB and EE should be more than
0.8% according to the “United States pharmacopoeia”
and “European pharmacopoeia” [5]. EB possessed anti-
stress, anti-fatigue [6], anti-oxidant [7], anti-irradiation,
anti-gastric ulceration, anti-inflammatory [8], immuno-
potentiating [9], immunomodulatory [10], anti-diabetic
effects [11,12] etc. Besides, EB and EE showed obvious
protective effects against neuritic atrophy and nerve cell
death [13,14]. Furthermore, EE exerted significant anti-
inflammatory effects by suppressing the gene expression. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chemical structures of eleutheroside B and eleutheroside E. Glc are connected by β-D-glycosidic linkages. (A) Eleutheroside B (B)
Eleutheroside E
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mia heart [15]. In addition, EE has the potential abilities
to alleviate behavioral alterations induced by sleep
deprivation [16] and fatigue both in physical and mental
fatigue [17].
Cytochrome P450 (CYP450), the most important
drug-metabolizing enzymes, with largest number and
highest abundance of CYP isoforms present in the liver.
It is well known that CYP450 play a vital role in the me-
tabolism of currently used drugs. Most drugs are metab-
olized through several major CYP isoforms. CYP3A4,
CYP2D6, CYP2C9 and CYP2E1 have been estimated to
be involved in the metabolism of approximately 85% of
the drugs in clinical practice [18]. Since these subtypes
metabolize numerous drugs, drug-drug interactions
(DDIs) can potentially occur when multiple drugs are
co-administered. Therefore, evaluation of effects on CYP
isoforms of drugs is important for the prediction of po-
tential DDIs. Inhibition of CYP450 enzymes is the most
important reason caused DDIs, which raises the toxicity
of drugs.
To our knowledge, this is the first study focus on the
potential role of EB and EE in CYP450-mediated DDIs.
The present study was performed to investigate the in-
fluence of EB and EE on the activities of CYP2C9,
CYP2D6, CYP2E1 and CYP3A4 in rat liver microsomes
and the mechanisms in vitro, which could be used to
predict the probability of herb-drug interactions, provid-
ing references for correlation studies and decrease the
risk of drug use.
Methods
Chemicals and reagents
Tolbutamide was purchased from Dr. Ehrenstorfer
GmbH (Augsburg, Germany). 4-hydroxytolbutamide and
6-hydroxychlorzoxazone were obtained from TorontoResearch Chemicals Inc. (North York, Canada). Dextro-
methorphan, dextrorphan and chlorzoxazone were
supplied by Sigma-Aldrich Co. (St Louis, MO, USA).
Testosterone was obtained from International Laboratory
Limited (San Bruno, CA, USA). 6β-hydroxytestosterone
was purchased from BD Biosciences Co. (Woburn,
MA, USA). Phenacetin, cortisone acetate, EB and
EE were from National Institute for the Control
of Pharmaceutical and Biological Products (Beijing,
China). NADPH was obtained from Roche Diagnostics
GmbH (Mannheim, Germany). All other reagents were
of HPLC or analytical grade.
Preparation of rat liver microsomes
Wistar rats (180 ± 20 g, male) were supplied by the Ani-
mal Experimental Center of Harbin Medical University
(Harbin, China), which was fully accredited by the Guide
for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved
by the Committee on the Ethics of the Harbin Medical
University (Permit Number: HMUIRB20120011), and the
rats were handled in a manner that met all the recommen-
dations formulated by the National Society for Medical
Research and Guidelines for the Care and Use of Labora-
tory Animals. Rat liver microsomes were prepared from
liver tissue by differential ultra-centrifugation [19], packed
and stored at −80°C for further analysis. These opera-
tions were carried out in the ice. Protein concentra-
tions of the microsomes were determined by the
method of Bradford [20].
Cytochrome P450 probe substrate assays
Tolbutamide and 4-methyhydroxylation assay for CYP2C9
The incubation system of CYP2C9 in vitro contained
phosphate buffer (100 mM, pH7.4), liver microsomal
protein (0.5 mg · mL-1), MgCl2 (10 mM), tolbutamide
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Pre-incubated 5 min, the reaction was initiated by add-
ing NADPH (1 mM concentration in incubation) and
the incubation systems were incubated at 37°C for
60 min. After incubation, 50 μL ice-cold acetonitrile was
added to terminate the reaction, and phenacetin of a
final concentration 20 μM was added as internal stand-
ard. With 5 min suspension, the mixture was centrifuged
for 30 min at 12000 r · min-1. The supernatant of 20 μL
was analyzed by the Waters HPLC system 2010 (Waters,
USA, with 600 pump, 996PAD UV detector and Milli-
pore Systems). Tolbutamide, 4-hydroxytolbutamide and
phenacetin were separated on a Diamonsil C18 reverse
phase column (5 μm, 4.6 mm× 200 mm). The column
temperature was set to 35°C. The mobile phase, at a flow
rate of 1 mL ·min-1, consisted of methanol and 0.1% acetic
acid (55:45, v/v). UV detection was at wavelength of
229 nm. The organic solvent which is at low concentration
(≤0.5%) in all incubation systems wouldn’t affect the activity
of enzymes. The yield of corresponding metabolites was
calculated by referring to a standard curve constructed
based on known concentrations of the pure metabolites.
Dextromethorphan and O-demethylation assay CYP2D6
Incubation conditions were the same as Section Tolbuta-
mide and 4-methyhydroxylation assay for CYP2C9. The
liver microsomal protein was 1.0 mg · mL-1 and tolbuta-
mide was replaced by 25 μM dextromethorphan. Reac-
tions were terminated by 80 μL ice-cold acetonitrile and
internal standard phenacetin (final concentration of
50 μM) was added, the denatured protein was removed
by centrifuged at 12000 r · min-1 for 30 min. The super-
natant of 20 μL was injected into the HPLC system, with
the mobile phase of methanol, water, phosphate and
triethylamine (42:58:0.15:0.3, v/v/v/v) at a flow rate of
1 mL · min-1, detection was at wavelength of 280 nm.
Chlorzoxazone and 6-hydroxylation assay for CYP2E1
Each incubation mixture (200 μL) included liver micro-
somal protein (0.75 mg. mL-1), MgCl2 (10 mM) in
100 mM phosphate buffer (pH7.4) and 25 μM chlorzox-
azone. With 5 min pre-incubation, all reactions were ini-
tiated by addition of NADPH (1 mM) and were carried
out in 37°C water bath for 30 min, and then were
stopped by addition of 150 μL ice-cold acetonitrile and
internal standard (80 μM phenacetin). After centrifuga-
tion at 12000 r · min-1 for 30 min, 20 μL of the super-
natant was injected into the HPLC system, and eluted
with methanol–water (47:53) at a flow rate of 1.0 mL ·
min-1, UV absorbance was monitored at 287 nm.
Testosterone and 6β-hydroxylation assay for CYP3A4
Testosterone solution (in methanol, final concentration
of 100 μM) was evaporated to dryness under nitrogen in40°C water bath, then additional reagents were added to
give a final incubation volume of 200 μL: liver micro-
somal protein (0.5 mg · mL-1) in 50 mM sodium phos-
phate buffer (pH7.4) and MgCl2 (10 mM). Following a
5 min pre-incubation, reactions were started with
addition of NADPH (1 mM). Following 30 min incuba-
tions at 37°C, reactions were stopped with organic solu-
tion (280 μL ice-cold acetonitrile), and cortisone acetate
was added as internal standard with final concentration
of 12.5 μM. The mixture was centrifugated at 12000 r ·
min-1 for 30 min, and the supernatant of 20 μL was
injected into the HPLC, with UV detection at 245 nm.
Mobile phase consisted of methanol and water (65:35,
v/v), and the flow rate was 1.0 mL · min-1.
Determination of Km and Vmax
The apparent Km (Michaelis constant) and Vmax (max-
imum reaction velocity) values were determined in a range
of concentrations of probe drugs. The concentrations were
as follows: tolbutamide 3.5~600.0 μM, dextromethorphan
3.5~400.0 μM, chlorzoxazone 5.0~300.0 μM, and testos-
terone 12.5~500.0 μM. The other incubation conditions
were the same as Section Cytochrome P450 probe sub-
strate assays.
Determination of effects of EB and EE on CYP450 activity
To evaluate whether EB and EE affect the activity of
CYP450, the probe substrate reaction assays were per-
formed with EB or EE at concentrations of 0, 2, 10, 25, 50,
150, 300 μM under the conditions described earlier, with
triplicate incubations for each concentration. The concen-
trations of respective probe substrates were selected ac-
cording to Km established in the enzyme kinetic assays
described above. The IC50 values (concentration of inhibi-
tor causing 50% inhibition of enzyme activity) were deter-
mined based on the concentration-inhibition curves.
Assay for enzymatic kinetic parameters
The exact inhibition constants (Ki values) were measured
and the modes of inhibition were determined for the com-
ponents exhibiting IC50 values of less than 200 μM. The
Ki values were determined in a range of concentrations of
probe substrates (approximately Km/2, Km, 2Km and 4Km)
and different concentrations of EB (0, 100, 200, 300 μM)
and EE(0, 100, 200, 300 μM). Dixon and Lineweaver-Burk
plots and the second plots showed the data graphically for
interpretation of inhibition mode. All experiments were
separately performed in three times.
Results
Enzymatic kinetic parameters for CYP450 in rat liver
microsomes
The apparent Km values for tolbutamide 4-methyhydroxy
lation, dextro- methorphan O-demethylation, chlorzoxazone
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liver microsomes were 94.80, 29.07, 30.42 and 103.81
μM, respectively. The Vmax values for tolbutamide 4-
methyhydroxylation, dextromethorphan O-demethylation,
chlorzoxazone 6-hydroxylation and testosterone 6β-
hydroxylation in liver microsomes were 1.57, 0.28, 0.05 and
2.71 nmol/min/mg protein, respectively.IC50 for EB and EE inhibition
The inhibitory potency of EB and EE were determined
based by the concentration-inhibition curves of the four
CYP isoforms. As shown in Figure 2, EB inhibited tol-
butamide 4-methyhydroxylation (CYP2C9) with an IC50
of 595.66 μM and chlorzoxazone 6-hydroxylation
(CYP2E1) with an IC50 of 193.20 μM. The IC50 values of
EE were 261.82 μM for CYP2C9 and 188.36 μM for
CYP2E1 (Figure 2), respectively. The results indicated
that EB and EE can inhibit CYP2E1 and CYP2C9 activ-
ities in rat liver microsomes. On the other hand, EB and
EE did not cause inhibition of CYP2D6, CYP3A4, the
IC50 values could not be extrapolated and calculated.Type of inhibition of CYP2E1 by EB and EE
To further characterize the inhibition of CYP2E1 activity
by EB and EE, Ki values were calculated and the inhib-
ition type were determined with EB and EE concentra-
tions of 0, 100, 200, 300 μM. Dixon and Lineweaver-
Burk plots showed that the inhibition of EB to CYP2E1
was best fit to a mixed-type, and the Ki value was evalu-
ated to be 183.95 μM from the secondary plot of the
slopes of Lineweaver-Burk plots versus the concentra-
tions of EB (Figure 3). Furthermore, kinetic study of the
effect of EE on CYP2E1 enzyme showed that the inhib-

























Figure 2 Concentration-inhibition curves of CYP enzymes by EB andDiscussion
The incubation experiment of liver microsomes is a gen-
erally used method for drug metabolism in vitro, which
is recommended by the relevant guidelines of the United
States [21]. The liver microsomes consist of a variety of
enzymes, and we chose tolbutamide, dextromethorphan,
chlorzoxazone and testosterone, which are extensively
used as probe substrates for CYP2C9, CYP2D6, CYP2E1
and CYP3A4 respectively in this study [22-25].
The present study addressed that EB and EE exhibited
weak inhibition against rat CYP2C9, CYP2E1 activity,
and no effect on CYP2D6 and CYP3A4 activity in rat
liver microsomes in vitro. The IC50 values of EE and EB
were 193.20 μM and 188.36 μM for CYP2E1, and
595.66 μM and 261.82 μM for CYP2C9, respectively.
Kinetic analysis suggested that the inhibition of CYP2E1
by EB was best fit to a mixed-type with Ki value of
183.95 μM, while the inhibition of CYP2E1 by EE was
also best fit to a mixed manner with Ki value of
171.63 μM. Consistently, Donovan et al assessed the in-
fluence of standardized extracts of ES on the activity of
CYP2D6 and CYP3A4 in normal volunteers, and found
that there were no statistically significant differences
in the pharmacokinetic parameters determined by
noncompartmental modeling, indicating that ES are
unlikely to significantly affect CYP3A4 and CYP2D6
activities [26].
Our results suggest that EB and EE have inhibition ef-
fects on CYP2C9 and CYP2E1 in rat hepatic micro-
somes. Studies show that the extrapolation of CYP2E1
between species appears to be quite well, and rat seems
to be best model for human in this respect [27]. Based
on the metabolic substrate studies, human CYP2C9 cor-
responds to rat CYP2C11, which has quite similar meta-
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Figure 3 Kinetic study of the effect of EB on CYP2E1 enzyme (A) Dixon plot of inhibition effect of EB on chlorzoxazone 6-hydroxylation
(CYP2E1). (B) Lineweaver-Burk plot of inhibitory effect of EB on chlorzoxazone 6-hydroxylation (CYP2E1). (C) Secondary plot of the slopes from
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Figure 4 Kinetic study of the effect of EE on CYP2E1 enzyme. (A) Dixon plot of inhibition effect of EE on chlorzoxazone 6-hydroxylation
(CYP2E1). (B) Lineweaver-Burk plot of inhibitory effect of EE on chlorzoxazone 6-hydroxylation (CYP2E1). (C) Secondary plot of slopes from
Lineweaver-Burk plot versus EB concentrations. Each data point represents mean of triplicate incubations.
Guo et al. BMC Complementary and Alternative Medicine 2014, 14:1 Page 5 of 7
http://www.biomedcentral.com/1472-6882/14/1
Guo et al. BMC Complementary and Alternative Medicine 2014, 14:1 Page 6 of 7
http://www.biomedcentral.com/1472-6882/14/1CYP2C9 metabolizes more than 10% of drugs clinically
used, including antidepressants, hypoglycemics, angio-
tensin II blockers, non-steroidal anti-inflammatory
drugs, S-warfarin, diclofenac, tolbutamide, glipizide,
losartan, flurbiprofen, naproxen, ibuprofen, fluoxetine,
sertraline, valproate, phenobarbital, phenytoin, fluvasta-
tin, tamoxifen, etc [16,28]. CYP2E1 also plays an important
role in the metabolism of many commonly pharmaceuticals
including nifedipine, erythromycin, acetaminophen, enflur-
ane, ethanol and halothane [16,28]. The inhibition can re-
sult in the increase of the plasma concentration and
toxicity of concomitant drugs, especially for those with nar-
row therapeutic windows such as warfarin, phenobarbital
and phenytoin. More attention should be paid when ES is
used with these drugs concomitantly. However, further
clinical investigation should be carried on to prove
whether inhibitions by EB and EE on CYP2C9 or
CYP2E1 may alter the pharmacokinetics of these drugs
and increase their adverse drug reactions when they
are co-administered with ES.
Previous studies have shown that concomitant admin-
istration of herbal preparations and pharmaceuticals
may affect drug metabolism and significantly increase
the risk of serious adverse reactions. For instance, the
interaction between warfarin and St. John’s wort have
been reported and the mechanism by which St. John’s
wort activates CYP450 enzymes is possibly the most
thoroughly researched idea [29]. In addition, a number
of the clinical relevance of herb interactions has been re-
ported, touching on interactions of Salvia (Danshen),
Flos carthami, Centella asiatica, Andrographis panicu-
lata, Silybum marianum, Acorus calamus and Golden-
seal with various CYP450 isoforms [30-36]. ES has been
widely used as a traditional herbal medicine and popular
herbal dietary supplements, and often co-administered
with many other drugs [37-41], the present study may
facilitate predicting possible herb-drug interactions
when ES is used in combination with other drugs,
and decrease the incidence of the CYP450-mediated
interactions.Conclusion
In conclusion, EB and EE inhibit CYP2C9 and CYP2E1
activity, but have no effect on CYP2D6 and CYP3A4 in
rat liver microsomes in vitro. Both compounds show
mixed-type inhibition of CYP2C9 and CYP2E1. The re-
sults suggest that both EB and EE could cause potential
drug-drug interactions with drugs that are metabolized
by CYP2C9 and CYP2E1. However, the inhibitory effects
of EB and EE on both CYPs were relatively weak and
further investigation is needed to evaluate whether the
weak inhibitory effects of both compounds on the two
CYP450 isoforms are clinically significant.Competing interests
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